封面
市場調查報告書
商品編碼
1622382

獸醫腫瘤學市場規模、佔有率、成長分析、按治療類型、按動物類型、按癌症類型、按最終用戶、按地區 - 行業預測,2025-2032 年

Veterinary Oncology Market Size, Share, Growth Analysis, By Therapy Type (Chemotherapy, Radiation Therapy), By Animal Type (Companion Animals, Livestock Animals), By Cancer Type, By End-User, By Region - Industry Forecast 2025-2032

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2023年獸醫腫瘤市場規模為2,594億美元,從2024年的2,907.9億美元成長到2032年的7,251.4億美元,預計複合年成長率為12.10%。

寵物癌症發生率上升和動物保健投資增加推動了獸醫腫瘤學市場的發展。寵物飼主在獸醫治療上的支出意願不斷增強以及政府的支持措施是推動該市場向前發展的主要趨勢。特別是,美國獸醫協會估計 25% 的狗一生中會遇到腫瘤,其中癌症往往是死亡的主要原因。此外,COVID-19 大流行加強了寵物與飼主之間的聯繫,迫使他們關注寵物的福祉。這一趨勢,加上探索新療法的獸醫臨床研究的增加,意味著強勁的成長軌跡。政府支持的舉措進一步強化了這一前景,並增加了獸醫癌症創新治療的前景。

目錄

介紹

  • 研究目的
  • 調查範圍
  • 定義

調查方法

  • 資訊採購
  • 二手資料和主要資料方法
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 全球市場展望
  • 供需趨勢分析
  • 按細分市場的機會分析

市場動態及展望

  • 市場概況
  • 市場規模
  • 市場動態
    • 促進因素和機遇
    • 抑制因素和挑戰
  • 波特的分析

主要市場考察

  • 關鍵成功因素
  • 競爭程度
  • 主要投資機會
  • 市場生態系統
  • 市場吸引力指數(2024年)
  • PESTEL分析
  • 總體經濟指標
  • 價值鏈分析
  • 價格分析
  • 監管環境
  • 案例研究

獸醫腫瘤學市場規模:依治療類型

  • 市場概況
  • 化療
    • 口服化療
    • 注射化療
  • 放射治療
    • 外部放射治療
    • 體內放射療法
  • 免疫療法
    • 單株抗體
    • 癌症疫苗
  • 外科手術
    • 腫瘤切除
    • 重組手術

獸醫腫瘤學市場規模:依動物類型

  • 市場概況
  • 伴同性動物
  • 家畜

獸醫腫瘤學市場規模:按癌症類型

  • 市場概況
  • 淋巴瘤
  • 肥大細胞癌
  • 惡性黑色素瘤
  • 乳癌和鱗狀細胞癌
  • 其他

獸醫腫瘤學市場規模:依最終用戶分類

  • 市場概況
  • 動物醫院
  • 獸醫診所
  • 調查機構
  • 其他

獸醫腫瘤學市場規模

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東/非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東/非洲

競爭資訊

  • 前5名企業對比
  • 主要企業市場定位(2024年)
  • 主要市場參與者所採取的策略
  • 近期市場趨勢
  • 公司市場佔有率分析(2024年)
  • 主要企業簡介
    • 公司簡介
    • 產品系列分析
    • 按細分市場分類的佔有率分析
    • 收益與前一年同期比較(2022-2024)

主要企業簡介

  • Zoetis Inc.(USA)
  • Elanco Animal Health(USA)
  • Boehringer Ingelheim(Germany)
  • Merck Animal Health(USA)
  • Virbac(France)
  • Ceva Sante Animale(France)
  • Vetoquinol(France)
  • Dechra Pharmaceuticals(UK)
  • IDEXX Laboratories(USA)
  • Heska Corporation(USA)
  • Aratana Therapeutics(USA)
  • Karyopharm Therapeutics(USA)
  • Regeneus Ltd.(Australia)
  • PetCure Oncology(USA)
  • Accuray Incorporated(USA)
  • Varian Medical Systems(USA)
  • Morphogenesis, Inc.(USA)
  • Nippon Zenyaku Kogyo Co., Ltd.(Japan)
  • Eli Lilly and Company(USA)
  • Bayer AG(Germany)

結論和建議

簡介目錄
Product Code: SQMIG35A2515

Veterinary Oncology Market size was valued at USD 259.4 Billion in 2023 and is poised to grow from USD 290.79 Billion in 2024 to USD 725.14 Billion by 2032, growing at a CAGR of 12.10% during the forecast period (2025-2032).

The veterinary oncology market is driven by the rising incidence of cancer among pets, coupled with growing investment in animal healthcare. Increased pet owner willingness to spend on veterinary treatment, along with supportive government initiatives, are significant trends propelling this market forward. Notably, the American Veterinary Medical Association estimates that 25% of dogs will face neoplasia in their lifetime, with cancer being the leading cause of death in many cases. Additionally, the COVID-19 pandemic has intensified the bond between pets and owners, promoting greater focus on pet well-being. This trend, combined with an increase in veterinary clinical studies exploring new treatments, signifies a robust growth trajectory. Government-backed initiatives further bolster this landscape, enhancing prospects for innovative cancer therapies in veterinary medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Veterinary Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Veterinary Oncology Market Segmental Analysis

Global Veterinary Oncology Market is segmented by therapy type, animal type, cancer type, end-user and region. Based on therapy type, the market is segmented into chemotherapy, radiation therapy, immunotherapy and surgery. Based on animal type, the market is segmented into companion animals and livestock animals. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer and others. Based on end-user, the market is segmented into veterinary hospitals, veterinary clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Veterinary Oncology Market

One of the primary factors propelling the veterinary oncology market is the increasing occurrence of cancer among companion animals, including dogs and cats. With pets enjoying longer life expectancies, they face similar health challenges as humans, particularly the risk of cancer as they age. This surge in cancer cases among pets has led to a heightened demand for advanced and effective oncology treatments. As pet owners become more aware of the importance of specialized cancer care, the need for innovative therapies and diagnostic solutions in veterinary oncology continues to grow, significantly boosting the market's expansion and development.

Restraints in the Veterinary Oncology Market

The veterinary oncology market faces notable restraints due to the high costs associated with cancer treatments for pets. Many pet owners find the expenses related to diagnostic tests, surgical procedures, medications, and ongoing follow-up care to be significant financial burdens. This elevated pricing can limit the accessibility of veterinary oncology services, making it challenging for some pet owners to pursue necessary treatments for their beloved animals. Ultimately, the financial constraints associated with veterinary oncology can deter pet owners from seeking potentially life-saving interventions, thereby impacting the overall growth and reach of this specialized market.

Market Trends of the Veterinary Oncology Market

The veterinary oncology market is witnessing a significant trend towards personalized medicine, mirroring advancements in human cancer care. As pet owners increasingly seek tailored treatment options, veterinary oncologists are focusing on customized interventions based on the unique genetic profiles and biomarkers of individual animals' cancers. This shift not only enhances treatment efficacy but also aims to reduce potential adverse effects, leading to improved quality of life for pets. The integration of advanced diagnostics and targeted therapies is expected to drive innovation in the market, ultimately expanding growth opportunities for veterinary oncology practitioners and contributing to the broader field of animal health.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Regulatory Landscape
  • Case Studies

Global Veterinary Oncology Market Size by Therapy Type & CAGR (2025-2032)

  • Market Overview
  • Chemotherapy
    • Oral Chemotherapy
    • Injectable Chemotherapy
  • Radiation Therapy
    • External Beam Radiation Therapy
    • Internal Radiation Therapy
  • Immunotherapy
    • Monoclonal Antibodies
    • Cancer Vaccines
  • Surgery
    • Tumor Removal
    • Reconstructive Surgery

Global Veterinary Oncology Market Size by Animal Type & CAGR (2025-2032)

  • Market Overview
  • Companion Animals
    • Dogs
    • Cats
  • Livestock Animals
    • Cattle
    • Sheep
    • Pigs

Global Veterinary Oncology Market Size by Cancer Type & CAGR (2025-2032)

  • Market Overview
  • Lymphoma
  • Mast Cell Cancer
  • Melanoma
  • Mammary And Squamous Cell Cancer
  • Others

Global Veterinary Oncology Market Size by End-User & CAGR (2025-2032)

  • Market Overview
  • Veterinary Hospitals
  • Veterinary Clinics
  • Research Institutes
  • Others

Global Veterinary Oncology Market Size & CAGR (2025-2032)

  • North America (Therapy Type, Animal Type, Cancer Type, End-User)
    • US
    • Canada
  • Europe (Therapy Type, Animal Type, Cancer Type, End-User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Therapy Type, Animal Type, Cancer Type, End-User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Therapy Type, Animal Type, Cancer Type, End-User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Therapy Type, Animal Type, Cancer Type, End-User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Zoetis Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Elanco Animal Health (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck Animal Health (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Virbac (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ceva Sante Animale (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vetoquinol (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dechra Pharmaceuticals (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • IDEXX Laboratories (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Heska Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aratana Therapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Karyopharm Therapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneus Ltd. (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PetCure Oncology (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Accuray Incorporated (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Varian Medical Systems (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Morphogenesis, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nippon Zenyaku Kogyo Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations